1-855-378-42281-855-378-4228
One of the out-patient rehabilitation alternatives for clients in Laguna who are battling with opioid dependence and addiction is opioid maintenance therapy. Licensed centers and doctors are authorized to give certain meds to opioid dependent clients, many of which are opioids also and are habit forming. With low enough amounts the user doesn't experience high feelings but also doesn't experience intense cravings and isn't experiencing opioid withdrawal. Methadone is the first medication administered for this sole purpose, but there are alternative options currently to pick from.
Methadone is an opioid and is meant to be taken at an outpatient clinic licensed to administer the drug, which is taken on a daily basis as a pill or liquid. The cost of the drug is about under $200 per month. Buprenorphine is also an opioid-based med, and is a pill often taken one day on, one day off. But different from Methadone that is only be given in highly structured medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The monthly cost of buprenorphine is approximately $300.00 a month for the generic of the medication. There is also a type of buprenorphine containing the drug naloxone, which is a drug which reverses the effects of opioids. Someone consuming this formulation, AKA Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken every day, and is priced about $450 per month. Naltrexone is an additional med taken in opioid maintenance therapy, but unlike the other medications aforementioned it's an opiate blocker and isn't an opioid. A person has the choice to take this drug as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents a person from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 per month.
For All Alcohol and Drug Rehabilitation Centers In Laguna, Click Here.
